Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Author(s)
Type
Journal Article
Abstract
We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.
Date Issued
2021-03-01
Date Acceptance
2020-12-14
Citation
American Heart Journal, 2021, 233, pp.141-148
ISSN
0002-8703
Publisher
Mosby
Start Page
141
End Page
148
Journal / Book Title
American Heart Journal
Volume
233
Copyright Statement
© 2020 Elsevier Inc. All rights reserved. . This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33358942
PII: S0002-8703(20)30407-5
Subjects
Cardiovascular System & Hematology
1102 Cardiorespiratory Medicine and Haematology
1117 Public Health and Health Services
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2020-12-22